TAMPA, Fla.—Immix, a global provider of commercial central station and remote SOC software for managed video and security services, has announced a partnership with Techevolution, a technology-hosting ...
LAS VEGAS — Immix, a provider of software for commercial monitoring centers, and Robotic Assistance Devices (RAD), a subsidiary of Artificial Intelligence Technology Solutions (AITX), have announced ...
– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL ...
LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL ...
LOS ANGELES, July 23, 2019 /PRNewswire/ -- Immix Biopharma, Inc--a clinical-stage biopharmaceutical company developing next-generation cancer therapies--announced today that it received a letter from ...
Absence of neurotoxicity of any grade in low-volume disease to-date highlights a significant safety profile for NXC-201, which is crucial for patient acceptance and regulatory approval. Company is on ...
Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results